---
title: "688336.SH (688336.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/688336.SH/news.md"
symbol: "688336.SH"
name: "688336.SH"
parent: "https://longbridge.com/en/quote/688336.SH.md"
datetime: "2026-05-21T10:43:52.916Z"
locales:
  - [en](https://longbridge.com/en/quote/688336.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/688336.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/688336.SH/news.md)
---

# 688336.SH (688336.SH) — Related News

### [From the annual report, A-share innovative drugs: performance overseas realized, R&D investment continues to grow](https://longbridge.com/en/news/285905879.md)
*2026-05-11T08:19:11.000Z*
> The annual report of A-share biopharmaceutical companies shows that the innovative drug sector has achieved net profit g

### [Sunshine Guojian Pharmaceutical: Net profit of 178 million yuan in the first quarter of 2026, a year-on-year increase of 73.00%](https://longbridge.com/en/news/283991117.md)
*2026-04-24T11:26:03.000Z*
> Sunshine Guojian Pharmaceutical announced that its operating revenue for the first quarter of 2026 was 431 million yuan,

### [Sunshine Guojian Pharmaceutical's net profit surged by 311% in 2025! How did the leading innovative drug company achieve tenfold growth?](https://longbridge.com/en/news/283141535.md)
*2026-04-17T11:25:02.000Z*
> Sunshine Guojian Pharmaceutical's net profit surged by 311% in 2025, with operating revenue reaching 4.199 billion yuan,

### [Innovative drug concept stocks have pulled back, with Salubris and other stocks falling over 6%](https://longbridge.com/en/news/282921654.md)
*2026-04-16T01:51:44.000Z*
> Innovative drug concept stocks have pulled back, with Salubris and Cosunter down over 6%, and Staidson BioPharm and Suns

### [The sales guidance growth for 2026 is optimistic, the innovative drug concept is experiencing a rebound, and Junshi Biosciences is favored again](https://longbridge.com/en/news/282486262.md)
*2026-04-13T02:54:11.000Z*
> On April 13th, the innovative drug concept rebounded, with Junshi Biosciences rising over 10%. Data from the National Me

### [](https://longbridge.com/en/news/281815620.md)
*2026-04-07T01:41:35.000Z*
> Innovative drug concept stocks rapidly plummeted, with NEPTUNUS hitting the daily limit, RemeGen falling more than 10%, 

### [](https://longbridge.com/en/news/281816091.md)
*2026-04-07T01:38:37.000Z*
> The A-share innovative drug sector has pulled back and weakened, with NEPTUNUS falling over 9%, Cosunter dropping over 6

### [Healthcare Industry Daily (04.01): Breakthroughs in Pharmaceutical Innovation](https://longbridge.com/en/news/281414019.md)
*2026-04-01T19:14:16.000Z*
> Sunshine Guojian Pharmaceutical expects a net profit growth of 311.49% year-on-year in 2025, with operating revenue reac

### [Golden Age Confirmed? Dozens of Stocks Surge in Bulk, Who is Igniting the Innovative Drug Market?](https://longbridge.com/en/news/281101589.md)
*2026-03-31T01:29:44.000Z*
> Recently, the innovative drug sector has performed strongly in the A-share market, with multiple stocks such as Sunshine

### [The innovative drugs in the STAR Market have risen against the trend, with Sunshine Guojian Pharmaceutical increasing by over 11%. The STAR innovative drug ETF China Universal (589120) saw both price and volume rise, at one point increasing by over 2%! With performance and valuation as threefold catalysts, innovative drugs are entering the "sweet spot" for hitting](https://longbridge.com/en/news/280974993.md)
*2026-03-30T05:34:11.000Z*
> On March 30th, the innovative drug sector in the STAR Market performed strongly in the A-share market, with the STAR Inn